SB 535 (Obesity Treatment Parity Care Access Act) requires California-regulated health care service plans and health insurance policies that include outpatient prescription drug benefits to cover three categories of obesity treatment: intensive behavioral therapy, bariatric surgery, and at least one FDA‑approved antiobesity medication. The mandate applies to contracts and policies issued, amended, or renewed on or after January 1, 2026, and includes limits on how insurers may restrict coverage for FDA‑approved drugs.
The bill is written as a parity/access measure: it removes the current gate that limits many prescription obesity treatments to patients classified as "morbid" or "severe" and directs regulators and payers to treat obesity treatments comparably to other conditions for purposes of utilization management and medical-necessity determinations. It excludes specialized dental/vision-only plans and Medicare supplement policies, and it notes existing regulatory cross‑references that insurers must still respect.
At a Glance
What It Does
Requires state‑regulated health plan contracts and insurance policies that cover outpatient prescription drugs to also cover intensive behavioral therapy, bariatric surgery, and at least one FDA‑approved antiobesity medication, effective for new or renewed contracts and policies on or after January 1, 2026. It bars plan coverage criteria for FDA‑approved antiobesity drugs from being more restrictive than the FDA‑approved indications.
Who It Affects
Applies to DMHC‑regulated health care service plans and DOI‑regulated health insurers that offer outpatient prescription drug benefits in California; does not apply to specialized dental or vision plans or Medicare supplement policies. It generally does not reach self‑funded ERISA employer plans, which remain governed by federal law.
Why It Matters
The measure expands the range of insurer‑covered obesity treatments and attempts to eliminate BMI‑threshold barriers that currently limit drug access, with implications for plan formularies, prior authorization policies, provider referrals for bariatric surgery, and pharmaceutical uptake. Compliance departments, plan actuaries, and provider networks will need to revisit coverage rules and capacity planning.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SB 535 creates a state law requirement that California health plans and insurance policies (subject to state regulation) that already offer outpatient prescription drug benefits must cover three categories of obesity care: intensive behavioral therapy, bariatric surgery, and at least one FDA‑approved medication for chronic weight management. The trigger for applicability is administrative: any contract or policy issued, amended, or renewed on or after January 1, 2026 must add these coverages if it offers outpatient prescription drugs.
The bill defines “FDA‑approved antiobesity medication” by reference to the FDA indication for chronic weight management and forbids plans from imposing coverage criteria that are more restrictive than those FDA indications. At the same time, it allows plans and insurers to use utilization management and medical‑necessity reviews, provided those reviews are carried out “in the same manner” as for other illnesses and conditions the plan covers.
The statute also lists narrow exclusions: specialized dental or vision‑only plans and Medicare supplement policies are outside its scope. The bill cross‑references existing prescription drug coverage rules in California regulation but does not repeal them.Mechanically, the law adds parallel provisions to the Health and Safety Code (for Knox‑Keene plans) and the Insurance Code (for DOI‑regulated policies).
Enforcement will operate through the existing regulatory frameworks: the Department of Managed Health Care and the Department of Insurance supervise covered entities. Because Knox‑Keene already makes willful violations criminal, the bill’s obligations create a state‑mandated local program context addressed in the text’s fiscal note language.Finally, the bill is framed with legislative findings that characterize obesity as a chronic disease with wide comorbidity and equity implications and that California’s current regulations limit drug coverage to patients meeting an older “morbid/severe” threshold.
The statute is designed to expand access earlier in the disease course and to reduce nonmedical barriers such as stigma and socioeconomic gatekeeping.
The Five Things You Need to Know
The mandate applies only to plans and policies that provide outpatient prescription drug benefits and takes effect for contracts and policies issued, amended, or renewed on or after January 1, 2026.
Coverage must include intensive behavioral therapy, bariatric surgery, and at least one FDA‑approved medication indicated for chronic weight management.
Plans may use utilization management and medical‑necessity review, but they must apply those controls in the same manner used for other covered illnesses or conditions.
Coverage criteria for FDA‑approved antiobesity medications cannot be more restrictive than the FDA‑approved indications for those drugs.
The statute expressly excludes specialized dental or vision‑only contracts and Medicare supplement policies from its requirements.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Legislative findings framing obesity as a chronic disease and equity issue
This section compiles medical organizations’ positions, public‑health data, and equity claims to justify the statute’s intervention. Practically, the findings are policy framing: they signal legislative intent to treat obesity similarly to other chronic diseases and to remove stigma‑based thresholds that limit access to care.
Knox‑Keene plans must add obesity treatments when they cover prescription drugs
Adds an obligation on health care service plan contracts regulated under Knox‑Keene: if a plan offers outpatient prescription drug benefits, any contract issued, amended, or renewed on/after Jan 1, 2026 must cover intensive behavioral therapy, bariatric surgery, and at least one FDA‑approved antiobesity medication. The provision defines the drug category by FDA indication, allows utilization management so long as it mirrors use for other conditions, and excludes dental/vision‑only and Medicare supplement contracts. It also preserves other existing prescription‑drug coverage rules referenced in state regulation.
Parallel requirement for DOI‑regulated health insurance policies
Imposes the same set of coverage requirements on health insurers regulated by the Department of Insurance: policies that include outpatient prescription drug benefits and are issued, amended, or renewed on/after Jan 1, 2026 must include intensive behavioral therapy, bariatric surgery, and at least one FDA‑approved antiobesity medication. Like the Knox‑Keene provision, it permits utilization management applied consistently with other conditions, sets the non‑restriction rule tied to FDA indications, and lists the same exclusions.
Enforcement context, criminality note, and fiscal framing
The bill includes a standard fiscal clause stating no state reimbursement is required for local agencies because costs arise from changes to crimes/infractions under existing law—reflecting that Knox‑Keene already treats willful violations as crimes. Practically, enforcement falls to DMHC and DOI under their existing oversight, and what changes is the regulated coverage baseline those agencies will supervise.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Patients with obesity who do not meet the older “morbid/severe” BMI thresholds — they gain earlier access to prescription antiobesity drugs and behavioral therapy without needing to progress to extreme BMI categories.
- Clinicians (primary care, endocrinologists, bariatric surgeons, behavioral health providers) — improved payer coverage reduces referral friction and prior‑authorization roadblocks, making it easier to recommend evidence‑based multimodal care.
- Communities disproportionately affected by obesity, including some communities of color and lower‑income Californians — the bill is explicitly framed to close equity gaps by reducing coverage barriers tied to socioeconomic status.
- Pharmaceutical manufacturers and pharmacies supplying FDA‑approved antiobesity medications — mandated coverage increases potential market access in California for drugs with FDA indications for chronic weight management.
Who Bears the Cost
- State‑regulated health plans and insurers (DMHC/DOI‑regulated) — they must expand covered benefits, update formularies and prior authorization rules, and absorb or price for additional drug and surgical expenditures.
- Employers purchasing fully insured plans — premium costs could rise if insurers pass increased utilization and drug costs through to premiums in the small‑group and large‑group markets.
- Provider systems and surgical programs — expanded coverage may produce higher demand for bariatric surgery and multidisciplinary behavioral programs, straining capacity where regional access is limited.
- State regulators (DMHC and DOI) — they will need to interpret the law’s ‘no more restrictive than FDA indications’ standard and monitor compliance, creating administrative and enforcement workload.
Key Issues
The Core Tension
The central dilemma is between expanding medically indicated access to obesity care—reducing stigma and earlier intervention—and preserving insurer tools to manage cost and ensure appropriate use; the bill restricts some payer controls while leaving others intact, forcing regulators to balance clinical access against budgetary and capacity constraints without clear statutory guidance on key implementation details.
SB 535 resolves one barrier to obesity treatment—insurance coverage thresholds—but raises implementation questions that regulators and plans will have to answer. The statute ties drug coverage limits to FDA‑approved indications and forbids more restrictive criteria, but it does not define terms such as “intensive behavioral therapy,” nor does it specify whether plans may continue to require documented prior attempts at lifestyle modification, specific BMI cutoffs that mirror FDA labels, or comorbidity requirements when those appear in labeling.
That leaves room for dispute about how permissive or prescriptive coverage must be in practice.
The bill permits utilization management so long as it is applied in the same manner as for other illnesses; this parity language limits arbitrary additional controls but does not eliminate standard tools like prior authorization, step therapy, or medical‑necessity reviews. A key open question is how regulators will interpret “the same manner” when obesity treatments typically intersect with ongoing chronic‑care management, long‑term medication adherence, and surgical pathways that require multidisciplinary evaluation.
Another tension concerns fiscal tradeoffs: broader drug and surgical coverage improves access but may raise premiums or shift costs to self‑funded ERISA plans (which likely remain outside the statute), producing uneven access across employer populations.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.